Front-line weekly chemotherapy with gemcitabine for unfit patients with non-small cell lung cancer (NSCLC)

Effective use of multi-arterial infusion chemotherapy for advanced non-small cell lung cancer patients: Four clinical specified cases

“…However, the patients enrolled in most of them were in PS of 0, 1, 2 and there were scarce reports which showed the benefits of chemotherapy for the patients in PS of 3, 4 [16,17]. Although palliative radiotherapy shows some degree of benefits on such patients [18,19], it is difficult to treat the patients with interstitial pneumonia or severe respiratory failure.…”

The safety and efficacy of EGFR TKIs monotherapy versus single-agent chemotherapy using third-generation cytotoxics as the first-line treatment for patients with advanced non-small cell lung cancer and poor performance status

“…1). A total of 1425 patients, 330 treated with EGFR TKIs and 1095 treated with single-agent regimens, were included in this study [10][11][12][13][14][15][16][17][18][19][28][29][30][31][32].…”

“…For other trials, substantial variabilities were not observed in the proportion of patients with female gender, disease stage IV and adenocarcinoma or bronchioalveolar carcinoma. All gefitinib trials and 3 of the 10 single-agent trials enrolled patients with PS 2 to 4 [12,15,17,[28][29][30][31][32]. All the EGFR TKIs trials and 5 of the 10 single-agent trials specifically enrolled poor PS patients while the other 5 single-agent trials also enrolled elderly without selection according their PS [ Preliminary report o f a large r trial (N= 1) Trials enroll ing pa tien ts p reviously trea ted by chemotherapy (N= 2) Retrosp ective study (N= 9, EGFR TKI s-7, singe-age nt ch emothe rapy-2) The proportion of ever-smoking patients ranged from 24% to 96% in EGFR TKIs trials while only 2 of the 10 single-agent trials reported this information, ranging from 67% to 82% [12,19].…”

“…Although, there is no consensus on standard treatment for these patients, single-agent chemotherapy appears to be a reasonable choice for them. This conclusion arises from the efficacy and tolerability observed with third-generation cytotoxics (gemcitabine, vinorelbine, taxanes) as single-agent therapy in both phase II and III trials [10][11][12][13][14][15][16][17][18][19]. However, this treatment appears only justified for patients with a PS of 2, there is no recommended treatment for PS 3 or 4 ANSCLC patients [20][21][22][23].…”

Inhibition of expression of vascular endothelial growth factor and its receptors in pulmonary adenocarcinoma cell by TNP-470 in combination with gemcitabine

“…These include inhibiting DNA replication and cell growth and masked DNA chain termination (Storniolo et al, 1997). It is widely used in lung adenocarcinoma as a first-line chemotherapy and has been shown to produce significant survival benefits (Ferrigno et al, 2004). However, single-agent systemic chemotherapy achieves objective response rates ranging from 10% to 25%.…”